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Stability of pharmaceutical products is important for 
patient’s safety1 and stability calculations of expiration 
date of the product2. Stability of pharmaceutical product 
means the physical and chemical integrity of dosage form 
and its ability to guard against microbial contamination3. 
Pharmaceutical products adopt various pathways of 
chemical degradation including hydrolysis, oxidation, 
deamination and cyclization4. Accelerated stability studies 
are performed in order to predict the long term stability of 
pharmaceutical products5. They also help to identify the 
major degradation products; degradation pathways and 
stability indicating potential of analytical procedure 
used6.These studies are performed by exposing the 
representative sample of pharmaceutical product to stress 
conditions of temperature, humidity, light and radiations. 
Most companies conduct some types of accelerated 
degradation studies but companies’ practices vary widely 
in term of when and how these studies are to performed8. 
Flurbiprofen is a chiral, 2-arylpropionic acid derived non-
steroidal anti inflammatory drug having potent 
cyclooxegenase non selective inhibition activity8, shorter 
biological half-life and stereoselective pharmacokinetics9. 
It is used for the treatment of musculoskeletal and joint 
disorders like arthritis and acute gout. Film coated 
flurbiprofen tablets are elegant in appearance and 
improved gastric tolerability11. 
The aim of this study was to conduct accelerated stability 
studies of 100mg film coated flurbiprofen tablets from 
different national brands in Pakistan in order to evaluate 
the parameters of dissolution, disintegration, hardness and 
drug potency (WHO guidelines for stability testing, 
2006)11 at different time intervals of 1, 3 and 6 months as 
function of temperature and relative humidity at tropical 
conditions according to ICH guidelines, 2003. 
MATERIALS AND METHODS 
Flurbiprofen 100 mg film coated tablets, which were 5 
months near to their expiration date, of five different 
national brands i.e. Flurbin®, Rubinol®, Flurle®, 
Frugesic®, Eyeflox® were collected randomly from Mass 
pharma (Pvt) Ltd. Lahore, Obsons Pharmaceuticals (Pvt) 
Ltd. Lahore, Leads Pharma (Pvt) Ltd. Islamabad, 
Mediceena Pharma (Pvt) Ltd. Lahore, P.D.H 
Pharmaceuticals (Pvt) Ltd. Lahore respectively. Hardness 
tests were performed on MH-1 Galvano Scientific while 
for disintegration and dissolution tests, basket-rack 
assembly USP 30 (Galvano Scientific) and six stations 
USP 30 type II paddle apparatus (Galvano Scientific) were 
used respectively. Assay for concentration of flurbiprofen 
was performed on Optizen 2010 UV and was also 
determined by titrometric analysis. All other chemicals 
used were of analytical grade and were used without any 
chemical modification. 
Accelerated Stability Studies 
Flurbiprofen 100mg film coated tablets in form of packs in 
triplets were placed in stability chamber with controlled 
temperature and humidity of class IV climatic conditions 
as recommended by ICH guidelines 2007. Temperature 
was maintained at 40 + 2oC and relative humidity was 
controlled by KCI solution at RH 75+5 %. 
Tablet hardness 
Hardness of tablets was determined by placing them in 
plungers of Hardness Tester, measuring the average force 
in Kilogram by triplicate of tests. 
Disintegration studies 
Disintegration studies were performed according to USP 
30 specifications. Six tablets were placed in basket rack 
assembly of apparatus. Basket was moved with frequency 
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of 29 to 32 cycles per minute in distilled water, maintained 
at 37 + 2oC. 
Dissolution studies 
In vitro drug release studies were performed by dissolution 
test USP 30 for 6 hours, using phosphate buffer at pH of 
7.20 ± 0.05 maintained at 37 + 2
o
C as dissolution medium 
for film coated tablet and measuring the absorbance at 
247nm at UV visible spectrophotometer. Sample of 5ml 
was first taken after 45 minutes and then after every 30 
minutes and replaced by fresh dissolution medium to 
maintain the volume. Concentration of drug in sample was 
measured, after filtration and dilution, by calibration 
curves and percentage drug release was calculated. 
Assay 
Assay was performed by two ways; 
Titrimetric Analysis 
20 tablets were crushed and powdered. Powder weighing 
equivalent to 200 mg flurbiprofen was dissolved in 50 ml 
(96%) methanol. This solution was titrated against 0.1M 
NaOH, determining end point potentiometrically. 1 ml of 
0.1M of NaOH is equivalent to 24.43mg of C15H13FO2
12. 
Spectrophotometric analysis 
Spectrophotometric analysis was performed on UV visible 
spectrophotometer. Standard was prepared of 0.01mg/ml 
by dissolving 100 mg of flurbiprofen in 100 ml of 0.01N 
NaOH and then diluting it.  Sample solution was prepared 
by crushing and powdering 20 flurbiprofen tablets and 
dissolving powder weighing equivalent to 100 mg 
flurbiprofen in 100 ml of 0.01N NaOH and diluting upto 
0.01mg/ml. Absorbance was measured at 247nm and 
percentage of flurbiprofen was determined as13 
Percentage of flurbiprofen = (A sample ×100)/A standard 
Where A is Absorbance.  Acceptable limits were 90-110%. 
Assay was performed as triplicate of both methods and 




Table 1: Hardness of different brands of flurbiprofen 100 mg film coated tablets 
Brands Hardness (average) 
(kg/cm2/tablet) 
One month Three month Six month 
Flurbin 7.6 7.5 7.1 
Rubinol 7.3 7.2 6.5 
Flurle 8.1 7.7 6.9 
Frugesic 7.8 7.5 6.8 
Eyeflox 8.5 8.1 7.2 
 
Disintegration studies 
Table 2: Results of disintegration studies of different brands of flurbiprofen 100 mg film coated tablets 
Brands Disintegration time (average) 
(min) 
One month Three month Six month 
Flurbin 8.10 7.95 7.10 
Rubinol 8.21 8.13 7.25 
Flurle 8.61 8.43 7.80 
Frugesic 8.95 8.65 8.15 
Eyeflox 8.25 8.05 7.88 
 
Dissolution studies 
Table 3: Results of dissolution studies of different brands of flurbiprofen 100mg film coated tablets 
Brands Dissolution (average) 
(%age) 
One month Three month Six month 
Flurbin 91.32 86.45 78.53 
Rubinol 95.82 89.33 80.52 
Flurle 99.24 92.52 77.83 
Frugesic 90.40 83.53 76.85 
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Assay 
Table 4: Results of assays of different brands of flurbiprofen 100 mg film coated tablets 
Brands Assay (average) 
(%age) 
One month Three month Six month 
Flurbin 99.76 97.65 91.5 
Rubinol 102.26 101.61 96.40 
Flurle 98.62 98.33 92.53 
Frugesic 95.39 94.99 90.81 
Eyeflox 102.10 101.85 95.33 
 
DISCUSSION 
Flurbiprofen is a potent NSAID been in clinical use for 
many years. Formulation tests recommended in 
pharmacopoeia monographs are useful in determining in 
vivo efficacy. Hardness of tablets, after keeping in stability 
chamber for 6 months at controlled temperature and 
humidity was not significantly affected up to 3 months of 
studies as tablet gains moisture and its hardness increases 
then subsequently loose it14 whereas hardness of all brands 
decreased after six months significantly. Disintegration 
and dissolution decreased in same manner during 6 months 
studies, under increased humidity. However difference of 
disintegration pattern from that of hardness can be justified 
due to excipients function15. Assay of five different brands 
was conducted by both spectrophotometer and titrimetric 
analysis, and results were calculated as average, and 
results were in the range of 90-110% USP 30 and there 
was no marked effect on assay of brands taken for studies. 
From above discussed data, flurbiprofen film coated 
tablets of all national brands have been found stable even 
after expiry date. Therefore, it has been concluded that 
stability study of flurbiprofen found equally accurate, 
reproducible, robust, and could be applied directly and 
easily to the pharmaceutical preparations of flurbiprofen. 
However excipients function was not taken into account 
which can impart deviation from above results. 
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